Cancer Intelligence Limited - Period Ending 2019-12-31

Cancer Intelligence Limited - Period Ending 2019-12-31


Cancer Intelligence Limited 04595666 false 2019-01-01 2019-12-31 2019-12-31 The principal activity of the company is the provision of medical research and consultancy services. The company also owns and manages offices. Digita Accounts Production Advanced 6.26.9041.0 true 04595666 2019-01-01 2019-12-31 04595666 2019-12-31 04595666 core:CurrentFinancialInstruments core:WithinOneYear 2019-12-31 04595666 core:Non-currentFinancialInstruments core:AfterOneYear 2019-12-31 04595666 bus:Micro-entities 2019-01-01 2019-12-31 04595666 bus:AuditExemptWithAccountantsReport 2019-01-01 2019-12-31 04595666 bus:FullAccounts 2019-01-01 2019-12-31 04595666 bus:SmallCompaniesRegimeForAccounts 2019-01-01 2019-12-31 04595666 bus:RegisteredOffice 2019-01-01 2019-12-31 04595666 bus:CompanySecretary1 2019-01-01 2019-12-31 04595666 bus:Director1 2019-01-01 2019-12-31 04595666 bus:Director2 2019-01-01 2019-12-31 04595666 bus:PrivateLimitedCompanyLtd 2019-01-01 2019-12-31 04595666 countries:AllCountries 2019-01-01 2019-12-31 04595666 2018-01-01 2018-12-31 04595666 2018-12-31 04595666 core:CurrentFinancialInstruments core:WithinOneYear 2018-12-31 04595666 core:Non-currentFinancialInstruments core:AfterOneYear 2018-12-31 iso4217:GBP xbrli:pure

Registration number: 04595666

Cancer Intelligence Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2019

 

Cancer Intelligence Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Cancer Intelligence Limited

Company Information

Directors

Prof J Gordon McVie

Ms Susi Burke

Company secretary

Mr Mark Longbottom

Registered office

11 Alma Vale Road
Clifton
Bristol
BS8 2HL

Accountants

PRWS (Bristol) Limited
Chartered Certified Accountants
11 Alma Vale Road
Clifton
Bristol
BS8 2HL

 

Cancer Intelligence Limited

(Registration number: 04595666)
Balance Sheet as at 31 December 2019

2019
£

2018
£

Fixed assets

405,858

528,879

Current assets

86,140

62,603

Prepayments and accrued income

745

33,838

Creditors: Amounts falling due within one year

(33,500)

(247,247)

Net current assets/(liabilities)

53,385

(150,806)

Total assets less current liabilities

459,243

378,073

Creditors: Amounts falling due after more than one year

(96,988)

(55,920)

Accruals and deferred income

(2,403)

(15,359)

 

359,852

306,794

Capital and reserves

359,852

306,794

1

General information

The company is a private company limited by share capital, incorporated in Engalnd & Wales.

The address of its registered office is:
11 Alma Vale Road
Clifton
Bristol
BS8 2HL
United Kingdom

These financial statements were authorised for issue by the Board on 16 September 2020.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2018 - 21).

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

For the financial year ending 31 December 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

 

Cancer Intelligence Limited

(Registration number: 04595666)
Balance Sheet as at 31 December 2019

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

Approved and authorised by the Board on 16 September 2020 and signed on its behalf by:
 

.........................................

Prof J Gordon McVie
Director